FDA Approves Sarepta Therapeutics' Gene Therapy for Duchenne Muscular Dystrophy.
TL;DR
The FDA has approved Sarepta Therapeutics' gene therapy treatment for children with Duchenne muscular dystrophy, despite questions about its clinical benefit.
Topics:businesshealthcare#clinical-benefit#duchenne-muscular-dystrophy#fda#gene-therapy#healthcare#sarepta-therapeutics
Want the full story? Read the original reporting
Read on Barron's